August 30, 2024 – Octant, Inc. (“Octant”), an AI-enabled drug discovery company developing correctors for misfolding diseases, announced today that CEO Sri Kosuri will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, at 1:50pm ET in New York, NY.
Octant is a small molecule drug discovery company developing correctors for protein misfolding diseases. Octant’s platform, The Navigator, combines high-throughput synthetic biology, generative chemistry, and AI/ML to discover and develop therapeutics against complex cellular mechanisms in human cells. Their pipeline is led by correctors programs for autosomal dominant Retinitis Pigmentosa (adRP) and Fabry Disease (FD), and includes several other programs across oncology and other serious diseases. For more information visit www.octant.bio.